Merck (MRK) Crossed Above the 20-Day Moving Average: What That Means for InvestorsZacks Investment Research • 05/16/24
Merck & Co., Inc. (MRK) BofA Securities 2024 Health Care Conference (Transcript)Seeking Alpha • 05/16/24
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse PipelineBusiness Wire • 05/15/24
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk MelanomaBusiness Wire • 05/13/24
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative IntentBusiness Wire • 05/09/24
Merck to Participate in the Bank of America Securities 2024 Healthcare ConferenceBusiness Wire • 05/08/24
Dow Jones Drug Giant Merck, Nvidia Eye Buy Points In Current Stock MarketInvestors Business Daily • 05/06/24
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) RegionGlobeNewsWire • 05/06/24
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaBusiness Wire • 05/01/24